Abstract Number: 841 • 2018 ACR/ARHP Annual Meeting
TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways
Background/Purpose: Tumor necrosis factor-a (TNF), a potent proinflammatory cytokine, activates two receptors: TNFR1 and TNFR2. Anti-TNF biological agents neutralize TNF, thus preventing both TNFR1 and…Abstract Number: 2615 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Background/Purpose: The aim of the study was to investigate the impact of smoking on disease activity, treatment adherence and treatment response in psoriatic arthritis (PsA)…Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…Abstract Number: 958 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…Abstract Number: 1301 • 2016 ACR/ARHP Annual Meeting
Analysis of Anatomical Sites Causing Dactylitis and Their Responsiveness to Change Under TNF-Therapy in Psoriatic Arthritis By High Resolution MRI
Background/Purpose: Results: The following sites were most commonly involved in dactylitis: collateral ligament enthesitis 11/12 (92%); extensor tendons enthesitis 5/12 (42%); flexor tenosynovitis 9/12 (75%),…Abstract Number: 1668 • 2016 ACR/ARHP Annual Meeting
Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models
Background/Purpose: Tumor necrosis factor-α (TNF) activates two receptors globally, TNFR1 and TNFR2. Neutralizing antibodies or soluble TNF receptors can inactivate TNF, blocking activity of both…Abstract Number: 2883 • 2015 ACR/ARHP Annual Meeting
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Background/Purpose: Fatigue is highly important to patients (pts) with psoriatic arthritis (PsA). Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved the signs and symptoms of active…Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…Abstract Number: 305 • 2013 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…Abstract Number: 2582 • 2012 ACR/ARHP Annual Meeting
Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Background/Purpose: To investigate whether methotrexate (MTX) or tumour necrosis factor inhibition (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with…Abstract Number: 2231 • 2012 ACR/ARHP Annual Meeting
Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: 2 Year Results of a Prospective Cohort Study
Background/Purpose: Treatment resistant psoriatic arthritis (PsA) may render a patient unwell, disabled and incapable of work with previous reports suggesting that unemployment levels among PsA…